"Viral vector manufacturing has transitioned from a niche industry to the cornerstone of the future of biopharmaceuticals," said Udit Batra, member of the Merck Executive Board and CEO, Life Science. "Few companies have the scale and quality systems in place for manufacturing commercial viral vector products. Building on our success in helping customers commercialize their gene therapies made possible by viral vectors, our expansion will help innovators produce at a scale that ensures these therapies reach more patients in need."
Merck's Life Science business sector facility in Carlsbad manufactures gene therapies for its customers globally. Gene therapy involves the delivery of a genetic payload into patient cells to produce a therapeutic effect such as correction of a mutated gene or retargeting of an immune cell to fight cancer. Diseases such as hemophiliaand cancer are being investigated using this technique where a single dose may cure the disease. Viral vectors are often called the most complex therapeutic manufactured today.The gene therapy market, which accounted for $1 billion in 2018, is expected to reach $10 billion by 2026, according to a recent Biotech Forecasts global market analysis and industry forecast.
Merck's new, 140,000-square-foot manufacturing facility will support viral and gene therapy production at the 1000-liter scale using its Mobius single-use equipment. The site is part of the Life Science business' expanding product and service offering to the viral and gene therapy marketplace. Merck has close to three decades of experience in cell and gene therapy, and its Carlsbad, California, U.S.A site has been involved in the gene therapy area since 1997, near the time that clinical trials for gene therapy began. In the interim, the company manufactured viral vectors for two cell and gene therapy products.
This expansion underscores Merck's continued investment in viral and gene therapies from clinical to commercial scale and marks the second major investment at its Carlsbad facility in recent years. In 2016, the investments resulted in nearly doubling its former production capacity. The upgraded facility grew from 44,000 square feet to 65,000 square feet. Today, the Carlsbad site is home to 16 modular viral bulk manufacturing cleanroom suites with single-use equipment and two fill/finish suites for gene therapy, viral vaccine and immunotherapy products. With the expansion, the company will add 11 suites, bringing the total to 27, used in various steps of manufacturing.
In addition to contract development and manufacturing services for viral vectors, Merck also provides seamless manufacturing and testing services at its pharma and biopharma testing sites globally.
Merck recognizes that cell and gene therapy has resulted in major advancements in medicine. The company supports these therapies under consideration of ethical and legal standards; it has established an independent, external Bioethics Advisory Panel. This panel provides guidance on various topics, including gene editing and stem cells usage, in which its businesses are involved. The company has also defined a clear operational position taking into account scientific and societal issues.
All Merck news releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About MerckMerck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices the company is everywhere. In 2019, Merck generated sales of 16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Performance Materials.
Photo - https://mma.prnewswire.com/media/1156781/Merck_Gene_Therapy.jpg
SOURCE Merck
Go here to read the rest:
Merck Boosts Commercial Viral Vector and Gene Therapy Manufacturing Capacity - PR Newswire UK
- Following Their Calling to Help Young Cancer Patients and Beyond - Stanford Children's Health - September 28th, 2024
- Greenberg Regenerative Medicine Celebrates Nearing 2 Years of Success with Pioneering VSEL Therapy - PR.com - September 28th, 2024
- Discovery clears hurdle in growing organs for transplants : Newsroom - UT Southwestern - September 26th, 2024
- Cell Therapy Market is Expected to Gain USD 60696.42 Million with a Growing CAGR of 19.20% by 2030 - openPR - September 25th, 2024
- Stem Cell Therapy Market To Reach USD 44 Billion By 2032 (Updated 2024) - Market.us Media - United States Market News - September 25th, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 23rd, 2024
- The new frontier of luxury travel is a $44,000 course of stem cells and a longevity club stocked with IV stations - Fortune - September 23rd, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 20th, 2024
- Exploring Regenerative Medicine and Its Impact on Modern Disease Management - Baltimore Post-Examiner - September 18th, 2024
- Stem Cell Therapy Market Dynamics: Size, Share, and Growth - openPR - September 16th, 2024
- Stem Cell Restore Review: Can It Boost Your Stem Cell Activity for Lasting Health? - Vashon-Maury Island Beachcomber - September 14th, 2024
- Stem Cell Therapy Market valued at USD 3.40 Billion by 2030 As Revealed In New Report - WhaTech - September 14th, 2024
- Stem Cell Manufacturing Market Projected to Witness Huge Growth by 2024-2031 As Revealed In New Report - WhaTech - September 14th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 12th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - StockTitan - September 10th, 2024
- Meso Numismatics Announces Cellgenics Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September - Newswire - September 10th, 2024
- Breakthrough in blood stem cell development offers hope for leukemia and bone marrow failure - News-Medical.Net - September 8th, 2024
- Stem Cell Therapy Market Is Estimated To Reach $928.6 Million by 2031 | CAGR 16.2% - EIN News - September 8th, 2024
- USC researchers receive funding to develop next generation of intelligent biocomputers - EurekAlert - September 8th, 2024
- Risk Factors and Indications for Stem Cell Transplants in MDS - Targeted Oncology - September 6th, 2024
- Cell Therapy Market Size to Hit USD 28.98 Billion by 2032, - GlobeNewswire - September 6th, 2024
- Blood stem cells grown in the lab for the first time ever - Earth.com - September 6th, 2024
- Top 3 Grants in Regenerative Medicine: August 2024 - RegMedNet - September 6th, 2024
- New approach moves cell therapy closer to treating many disorders - Medical Xpress - September 4th, 2024
- Stem Cell Therapy Mexico: R3 Stem Cell Unveils Innovative and Affordable Non-Invasive Solutions - openPR - September 4th, 2024
- What Sets Immunotherapy Regenerative Medicine Apart in a Crowded Regenerative Market? - Flaunt Magazine - September 2nd, 2024
- Tiny Test Tubes Sort Stem Cells for Improved Therapy - The Scientist - August 31st, 2024
- Dr. Crandall: Stem Cell Treatment Heals the Heart - Newsmax - August 31st, 2024
- From stem cells to technology, the next Wisconsin RISE initiative focuses on improving health - University of Wisconsin-Madison - August 29th, 2024
- aHSCT Stem Cell Therapy for MS | National MS Society - National MS Society - August 29th, 2024
- Are Stem Cells the Secret to Anti-Aging? - The Edge - August 22nd, 2024
- A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders - Cureus - August 22nd, 2024
- Scientists discover method to activate dormant stem cells in the brain - Medical Xpress - August 20th, 2024
- New way to extend 'shelf life' of blood stem cells can improve gene therapy - Medical Xpress - August 20th, 2024
- Where Are the Cell Therapies for Type 1 Diabetes? - Inside Precision Medicine - August 14th, 2024
- BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire - August 14th, 2024
- Stem Cell Therapy Market to expand to a market value of USD 3.40 Billion by 2030, with a CAGR of 13.4 percentage - openPR - August 14th, 2024
- Stem cell therapy unveiled: Discover the truth and boost donor rates - IOL - August 12th, 2024
- Stem Cell Therapy Market Set to Skyrocket to $48.89 Billion by 2033, Fueled by 13.2% CAGR - BioSpace - August 10th, 2024
- T.J. Watt Reveals He Received Stem Cell Treatment On Knee This Offseason - Steelers Depot - August 10th, 2024
- Anti-aging enthusiasts are getting $16,500 injections to make their knees young again - Business Insider Nederland - August 10th, 2024
- Regenerative Medicine Market Exclusive Insights on Size, Share and Profit - WhaTech - August 8th, 2024
- Fresh Study Reveals the Mesenchymal Stem Cells Market Trends, Strategy and Overview - WhaTech - August 6th, 2024
- Allogeneic Stem Cell Transplantation Market Exclusive Survey Report with Detailed Analysis to 2031 By Top R... - WhaTech - August 6th, 2024
- Salk awarded $3.6 million by the California Institute for Regenerative Medicine to advance research on brain aging - Salk Institute - August 2nd, 2024
- Professor awarded grant to study stem cell therapy for inflammatory bowel disorders - Mercer University - August 2nd, 2024
- Stem cell therapy advances: MSCs show potential in managing COVID-19 and influenza infections - News-Medical.Net - July 31st, 2024
- Scientists aboard international space station perform stem cell research and biomanufacturing in microgravity - BioProcess Insider - July 31st, 2024
- UCLA receives $2 million to develop regenerative medicine therapies for spinal cord injury - UCLA Newsroom - July 31st, 2024
- The Phoenix of stem cells: pluripotent cells in adult tissues and peripheral blood - Frontiers - July 31st, 2024
- Regenerative Medicine Market to Reach USD 194.9 Billion by 2032 - Market.us Media - United States Market News - July 31st, 2024
- Stem Cell Exosome Therapeutic Market Business Insights, Key Trend Analysis - Economica - July 31st, 2024
- One of the 7 people cured of HIV tells his story. Can his cure work for others? - Michigan Public - July 31st, 2024
- Novel stem cell treatment for osteoarthritis reduces pain by 58% - NewsBytes - July 30th, 2024
- Stem Cell Manufacturing Market Size To Reach $21.8 Billion By 2028 As Revealed In New Report - WhaTech - July 30th, 2024
- PRP, stem cell therapyhelp in curing infertility - The Times of India - July 30th, 2024
- Australian researchers develop a donor stem cell therapy for the successful treatment of osteoarthritis - News Hub - July 28th, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 28th, 2024
- Enggartiasto Lauds Stem Cell Therapy at RSCM - Jakartaglobe.id - July 28th, 2024
- Investigating the effect of alemtuzumab in allogeneic hematopoietic cell transplantation - Medical Xpress - July 28th, 2024
- Does This 'Stem Cell' Therapy Contain Any Actual Stem Cells? - Medscape - July 22nd, 2024
- Stem Cells and Malignant Mesothelioma - Mesothelioma.net Blog - July 18th, 2024
- Selma Blair on Getting Back on Track With MS Treatment: People Dont Get How Expensive It Is to Be Disabled - Hollywood Reporter - July 18th, 2024
- Common therapies contain different cell types, study finds - News-Medical.Net - July 18th, 2024
- Stem Cell Therapy with Saffron Extract Promotes Uterine Healing - Natural Science News - July 18th, 2024
- Half-matched stem cell transplant on 11-yr-old boy - The Times of India - July 12th, 2024
- Efficacy and Safety of Stem Cell Therapy for Orthopedic Conditions, Including Osteoarthritis and Bone Defects - Cureus - July 8th, 2024
- Stem Cell Therapy Market Poised to Reach USD 52.1 Billion by 2034 at a 12.1% of CAGR - PharmiWeb.com - July 8th, 2024
- "Living Fillings" Could be the Future Thanks to Stem Cells - NewBeauty Magazine - July 8th, 2024
- R3 Stem Cell Wins 2024 Global Regenerative Medicine Company of the Year for Third Time - EIN News - July 8th, 2024
- NUS Medicine team aims to start clinical trial of targeted therapy for deadly brain cancer in 2025 - The Straits Times - July 8th, 2024
- Sorting therapeutic stem cells by function improves healing after heart attack, lab study shows - Medical Xpress - July 4th, 2024
- July: cruk-grant | News and features - University of Bristol - July 4th, 2024
- Stem cell therapy shows promise for hirschsprung disease - Open Access Government - June 30th, 2024
- Stem Cells & Other Injectable Treatments: Solution or Scam? Episode 3 of 'The Bone Whisperers' Podcast - NYU Langone Health - June 28th, 2024
- Modulation of adipose-derived stem cell behavior by prostate pathology-associated plasma: insights from in vitro ... - Nature.com - June 28th, 2024
- Advancing regenerative medicine therapies UCI News - UCI News - June 26th, 2024
- Stem cell therapy could be breakthrough against type 1 diabetes - Medical Xpress - June 26th, 2024
- Paving the Way Toward Transplantation: NIH Awards Support Ophthalmology Retinal Research - University of Colorado Anschutz Medical Campus - June 26th, 2024
- Stem Cell Therapy Could Be Breakthrough Against Type 1 Diabetes - The Caledonian-Record - June 26th, 2024
Recent Comments